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Abstract
Infants born very prematurely have a greatly increased risk of suffering permanent
neurologic sequelae such as cerebral palsy (CP), a leading cause of physical disability in
childhood (Doyle, Crowther, Middleton, Marrett, and Rouse, 2010; Stanley and Crowther,
2008). The risk of developing CP increases exponentially as gestational age at birth decreases
(Ancel, Livinec, Larroque, et al., 2006). Observational studies conducted during the 1980s and
1990s found pre-term infants exposed in utero to magnesium sulfate (MgSo4) had decreased
incidence of CP (Cahill, Stout, and Caughey, 2010). This paper compares data from several
randomized trials as well as meta-analyses to determine whether a relationship exists between
antenatal MgSo4 exposure and decreased incidence of CP.
Defining the Problem
CP is defined by O'Shea (2008, pg 35), as "a disorder in posture and movement due to a
defect in or lesion of the immature brain." This disorder results in permanent, non-progressive
symptoms ranging from mild tremor to quadriplegia (Hayes, 2010). Sensation of the hands is
impaired in about half of all cases and chronic pain is reported by more than 25% of adults. Up
to 80% of affected individuals have at least some impairment of speech (Odding, Roebroeck, and
Stam, 2006). Low visual acuity is reported in almost 75% of all affected children (Odding et sl.,
2006). 50% of all children have gastrointestinal and feeding problems, and stunted growth occurs
in 25% (Odding et al., 2006). Significant monetary costs are also associated with CP, both for
affected persons, and society in general. A 2004 report by the United States Center for Disease
Control and Prevention estimated lifetime costs, including medical, non-medical, and
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productivity losses, for CP patients born in the year 2000 to reach 11.5 billion dollars (Honeycut,
Dunlap, Chen, al Homsi, Grosse et al., 2003).
Background
CP is the most common cause of physical disability in children (Reddihough and
Collins, 2003), affecting approximately 3.6 per 1000 or about 1 in 246 individuals (YearginAllsopp, Doernberg, Benedict, Kirby, and Durkin, 2008). While the prevalence of CP has
remained stable for two decades (Hankins and Speer, 2003), Crowther et al. (2010) found the
prevalence among very premature infants (born less than 34 weeks gestation), and very low
birthweight infants (born weighing less than 1500 grams), is rising. This rise is likely
attributable to the a general rise in the rate of pre-term births.
In the United States 12.8% of births occur prematurely in 2006, up 21% from 1990,
with infants as young as 23 weeks gestation now commonly surviving the neonatal period
(Cahill et al., 2010; Doyle, et al., 2010). This is potentially problematic as the risk of
developing CP is inversely related to gestational age at birth, with term infants having 0.1%
prevalence (Cahill, et al., 2010) compared to a nearly 20% prevalence in infants born before 26
weeks gestation; a 200 fold increase (Ancel et al., 2006). The correlation between very early
birth and increased prevalence of CP is likely due to the over-all immaturity, putting pre-term
infants at increased risk of neurologic insult.
Describing a specific etiology of CP is difficult as its origins are often multifactorial or
unknown (Lawson and Badawi, 2003; Reddihough and Collins, 2003). Prenatal events are
thought to be responsible for approximately 70-75% of all cases of cerebral palsy, although it is
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usually impossible to determine the exact nature and/or timing of the damaging event
(Reddihough and Collins, 2003). The remaining 25-30 % of CP cases are thought to result from
an insult to the brain during birth or the neonatal period resulting in a permanent change in
brain structure or function (O'Shea, 2008). Neonatal events known to increase the risk of
neurologic injury and CP include intracranial bleeding, hypoxic ischemic injury, septicemia,
multiple gestation and others (Reddihough and Collins, 2003).
Like the etiology of CP, the exact mechanism of MgSo4 in providing neuroprotection
remains unknown and may be multi-faceted. There is, however, evidence in animal studies that
MgSo4 may augment secondary effects of neurologic injury. Research by Perlman (2006)
found hypoxic brain injury to cause cell death in two phases. The initial insult can cause
immediate neuronal demise, however, a secondary process also causes significant neuronal loss
for approximately 72 hours after the initial event. In this period, two physiologic changes occur.
Beginning 6 hours after the injury, the cells' injured mitochondria begin to fail and cannot meet
the metabolic needs of the cell. At the same time, neuronal cells become hyper-excitatory and
begin to accumulate calcium, produce oxygen free radicals and excitotoxins, and form nitric
oxide within the cells, all of which lead to cell death. Perlman also found an increased rate of
apoptosis (spontaneous cell death) after neurologic injury. This evidence is significant as
Marret et al. (2007) found MgSo4 adminstration to have multiple neuroprotective roles after a
neurologic insult in rats, pigs, and mice. These effects include decreased excitotoxin release,
decreased apoptosis, prevention of modification of the nuclear cell membrane, and over-all
improvement in neurologic function (Marret et al., 2007). These findings, as well as a growing
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need to decrease neurologic sequelae in pre-term infants, have led to multiple studies of MgSo4
in humans.
Literature Review
Despite many attempts at finding therapies to reduce the rates of CP and neurologic
injury both pre and postnatally, few have proven successful in randomized, controlled trials
(Marret, Doyle, Crowther, and Middelton, 2007). However, several observational studies
conducted during the 1980's and 1990's showed infants whose mothers received MgSo4, either
as a tocolytic agent or to manage pre-eclampsia, had a markedly decreased risk of developing
CP (Nelson and Grether, 1995; Stanley and Crowther, 2008). These finding were largely reaffirmed in multiple prospective, randomized trials conducted from 1995-2008. Four of five
studies conducted administered MgSo4 specifically for neuroprophylaxis, the fifth (MAGPIE)
studied the efficacy of MgSo4 as treatment for pre-eclampsia, but also measured neurologic
outcomes (Cahill, 2010; Marret et al., 2007). These studies are individually reviewed below.
The largest study, Beneficial Effects of Antenatal Magnesium Sulfate (BEAM), was
conducted from 1997-2007 (Rouse, Hirtz, Thom, Varner, Spong, 2008). The study included
2471 women presenting from 24.0 to 31.6 weeks gestation with advanced preterm labor or
premature rupture of the membranes and no recent exposure to magnesium sulfate. Participants
were randomized to receive either intravenous magnesium sulfate or masked study drug
placebo. Those receiving MgSo4 were given a 6 gram loading dose followed by a 2 gram/hour
infusion (or equivalent rate for placebo). If after 12 hours, delivery did not occur and was not
anticipated, the infusion was stopped. Standard clinical management and therapy was
maintained for all study patients.
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Rouse et al., (2008), found fetal exposure to magnesium sulfate before anticipated
preterm delivery did not reduce the combined risk of moderate or severe cerebral palsy or death
(11.3% and 11.7%, respectively; relative risk, 0.97; 95% confidence interval [CI], 0.77 to 1.23),
but did reduce the rate of CP among survivors (1.9% vs. 3.5%). The risk of death did not differ
significantly between the groups (9.5% vs. 8.5). No woman had a life-threatening event during
the trial.
The PreMAG study (Marret, Marpeau, and Benichou, 2008) was conducted in France
from 1997-2003 on women less than or equal to 33 weeks gestation. The trial enlisted 286 and
278 women, respectively, who were randomly assigned to receive a single infusion of 4 gm of
MgSO4 or 0.9% saline. Pediatricians, who were blinded to treatment, evaluated motor and
cognitive functions by using a questionnaire with developmental items extracted from the
Amiel-Tison and Denver scales and the European Cerebral Palsy Network definition (Marret et
al., 2008). When direct examination was not possible, assessment was performed through
parent telephone interview. All assessments were completed at 24 months of age.
Results of the PreMag study showed a statistically significant decreases in both death or
CP (16.1% Vs 20.2%, respectively), as well as a decrease in CP over-all (7% Vs. 10.2%,
respectively). Also important, the PreMag study demonstrated no increase in maternal or
pediatric mortality (Marret et al., 2008).
The ACTOMgSO4 trial (Crowther, Hiller, Doyle, and Haslam, 2003), was conducted
from 1996-2000 in New Zealand and Australia and had a total of 1062 women enrolled. All
enrollees were less than 30 weeks gestation and expected to give birth within 24 hours.
Participants in the experimental group received a 4g loading dose of MgSo4 followed by
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1g/hour maintenance until birth. Those in the control group received an equal volume of saline.
Survivors were examined until they reached 2 years of age by pediatricians and psychologists.
The study found pediatric mortality, defined as total number deaths prior to exam at 24 months
of age, was reduced (13.8% from 17.1%), as well as combined death or CP (19.8% from
24.0%), however, neither were statistically. None-the-less, findings of substantial gross motor
dysfunction and combined death or substantial gross motor dysfunction were reduced at
statistically significant levels (3.4% Vs. 6.6% and 17.0% Vs. 22.7 %, respectively).
The MAGPIE study (Altman, Carroli, Duley, Farrell, Moodley, et al., 2002), was
conducted from 1998 to 2001 with a total of 10,141 women enrolled. The trial was not focused
on MgSo4 as a neuroprotective agent, but on MgSo4 as an effective treatment for preeclampsia. This study enrolled women who were expected to give birth within 24 hours of
admission. An initial dose of 4 gm MgSo4 was given initially followed by 1gm/hr drip over 24
hours of a series of 5 gm intramuscular injections (IM) given every 4 hours. The placebo group
received an identical volume of saline given over the same schedule. While the primary focus
of MAGPIE was maternal health, the authors also included information on fetal
neuroprotection for infants born at less than 34 weeks gestation (n= 805).
Results from the MAGPIE study neither supported nor contradicted the use of MgSo4
for neuroprotection. Prevalence of CP in the treatment group was 3% vs. control 3%, and the
outcome of death or CP 41.8% in the treatment group and 40.1% in the control (Altman et al.,
2002). Importantly, the MAGPIE study demonstrated no statistically significant increase in
mortality among treated infants. However, treatment was associated with a 5 % increase in Csection rate.
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The MagNET study (Mittendorf, Dambrosia, Pryde, Lee, Gianopoulos, 2002),
conducted from 1995-1997 had a total enrollment of 149 women who were between 25 and 33
weeks gestation and in pre-term labor. The study had two arms, a tocolytic arm and a
preventative arm. Women dilated less than 4 cm were included in the tocolytic arm and
received either 4gm bolus of MgSo4 followed by 2-3 gm/hour maintenance or an alternative
tocolytic. Women dilated to 4 or greater were in the preventative group and received either a 4
gm MgSo4 bolus or saline placebo. This trial was terminated prematurely due to concerns the
treatment group had increased mortality (N= 10, 11.8% in treatment group versus 1 or 1.2% in
the placebo group. Increased infant mortality was only noted in the tocolytic arm, which
required longer (unlimited) courses of treatment. This was the only study to show a statistically
significant increase in infant mortality rates among infants treated with MgSo4. Results of all
five trials are listed in table 1-1 below.
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Table 1-1: Rates of pediatric mortality, cerebral palsy and death or cerebral palsy in
randomized controlled trials of antenatal magnesium sulfate therapy where fetuses were <34
weeks gestational age at randomization (adapted from Marret et al, 2007).

Study
(ref. no.)

Randomized

Mortality

M: n =

M: n =
n=
11.8%
(10)
13.8%
(87)
9.5%
(99)
41.3%
(167)
9.4%
(33)

C: n
=

MagNET
2002
ACTOMgSO4
2003
BEAM
2004
MAGPIE
2006
PreMag 2006

85

80

629

626

1041

1095

404

401

352

336

Cerebral palsy
C:
1.2%
(1)
17.1%
(107)
8.5%
(93)
39.4%
(158)
10.4%
(35)

M: n =
n=
3.5%
(3)
5.7%
(3)
2%
(20)
0.5%
(2)
6.2%
(22)

C:
3.8%
(3)
6.7%
(42)
3.4%
(38)
0.7%
(3)
7.4%
(25)

Death or cerebral
palsy
M: n =
C:
n=
15.3%
5.0%
(13)
(4)
19.6%
23.8%
(123)
(149)
11.2%
11.9%
(118)
(131)
41.8%
40.1%
(169)
(161)
15.6%
17.9%
(55)
(60)

Several meta-analyses have also been completed to assess the efficacy and safety of
MgSo4 prior to preterm birth. This review includes a Cochrane review, as well as three others,
all of which analyzed the same five clinical trials using the primary outcomes of fetal or infant
demise by 1 year of age, CP, moderate to severe CP, and a composite outcome of death or CP
by 2 years of age. For this analysis, outcomes were sub-categorized into trials looking at
MgSo4 specifically for neuroprotection, and MgSo4 given for other maternal indications such
as hypertension or seizure prophylaxis. All included meta-analyses, summarized below, came
to similar conclusions and support the use of MgSo4 for antenatal neuroprotection.
When all five trials are considered, using antenatal MgSo4 had no significant effect on
the combined outcome of death or CP (RR 0.94; 95% CI 0.78-1.12) (Simhan and Himes, 2010).
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However, for the four trials designed to specifically assess neuroprotective effects of MgSo4,
there was a significant reduction in death or CP (RR 0.85; 95% CI 0.74-0.98). There was no
significant effect on pediatric mortality rates in either subgroup. There was a significant
reduction in the risk of cerebral palsy (overall RR 0.68; 95% CI 0.54-0.87; neuroprotection
trials subgroup RR 0.71; 95% CI 0.55-0.91) and of moderate to severe CP in the
neuroprotection trials subgroup (RR 0.64; 95% CI 0.44-0.92). The absolute risk of CP was 3.7
percent for fetuses exposed to MgSo4 versus 5.4 percent for unexposed fetuses, giving an
absolute risk reduction of 1.7 percent (Simhan and Himes, 2010). There was also a reduction in
risk of substantial gross motor dysfunction (overall RR 0.61; 95% CI 0.44-0.85;
neuroprotection trials subgroup RR 0.60; 95% CI 0.43-0.83), but not in any other neurological
outcome.
It is worth noting that there were competing outcomes noted in these analyses,
specifically the finding of no significant effect of MgSo4 on the combined outcome of death or
CP in the overall group of trials and in the subgroup looking exclusively at trials for
neuroprotection. Simhan and Himes (2010), believe it is possible that the lack of statistical
significance of the combined outcome is due to an increased risk of death in a subgroup of
fetuses or infants, as suggested by two trials. While this finding should give providers pause,
increased mortality has not been demonstrated in other clinical trials of MgSo4, including the
MAGPIE trial, which had over 10,000 participants (Altman et al., 2002). It should be noted,
too, that the combined outcome of "death or cerebral palsy" was reduced significantly when
only trials designed specifically to assess the neuroprotective effect of magnesium sulfate were
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analyzed (Simhan and Himes, 2010). One factor that might be considered when weighing the
risk and benefit of antenatal MgSo4 therapy for neuroprotection is gestational age.
A meta-analysis by Cahill et al., 2010, concluded that MgSo4 can reduce the risk of
CP, particularly in infants born at or below 32 weeks gestation. Cahill acknowledges that, while
much data is still needed in regard to the use of MgSo4 for neuroprotection, it has been proven
safe over decades of perinatal use and should be considered for neuroprotection in infants less
than 32 weeks gestation, an age where the number of infants needed to treat (NNT) to prevent
one case of CP is relatively low. Table 2-1, below, illustrates the inverse relationship between
the NNT with MgSo4 and gestational age at birth. Table 2-1 also outlines a summary of
baseline risk that an infant will develop CP based on gestational age if no treatment were
given.
Table 2-1: Illustration of numbers needed to treat with MgSo4 stratified by gestational age
(Cahill et al., 2010)
Gestational age

Baseline risk

Risk CP with

Risk Difference

Number

(weeks)

CP (%)

MgSo4 (%)

(%)

Needed to treat

22-27

14.6

8.0

6.6

15

28-31

6.2

3.4

2.8

35

32-36

0.7

0.4

0.3

333

>37

0.11

0.06

0.05

2000
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Treatment Risks
While three of the five original research trials, as well as the authors of all four metaanalyses, recommend use of antenatal MgSo4 as a neuroprophylactic treatment, it is not
without risks. Crowther et al., (2010) found multiple adverse effects in women receiving the
MgSo4 treatment including flushing, sweating, nausea, vomiting, headache, and tachycardia.
All of these side-effects were temporary and resolved after treatment was ceased. Infants born
to mothers treated with MgSo4 also risk temporary side effects such as decreased tone and poor
feeding (Macdonald, Mullett, and Seshia, 2005). Importantly, only the MagNet study showed
an increased risk of mortality with MgSo4 administration and that increase was only noted in
the prophylaxis group (Mittendorf et al., 2002). Cahill (2010) also points out that there is
inherent risk in using a therapy in which the mechanism of action is not well understood. Nonethe-less, as the number of pre-term births and the prevalence of CP among premature infants
rises, so do the potential benefits of MgSo4, particularly in infants less than 32 weeks gestation.
Implications and Recommendations
As improvements in medical care and technology continue to lower fetal age of viability
and increase the number of infants who survive severe neurologic injuries, it is urgent to find
therapies to prevent the crippling, life-long effects of CP. While additional research is needed to
better understand the precise ways in which MgSo4 affects the brain, the safety of MgSo4 has
long been established in maternal-fetal medicine (Altman et al., 2002). Given the research cited
above, as well as a recommendation by the World Health Organization, it may be appropriate
for providers to consider MgSo4 for nueroprophylaxis on a broader scale (Lumbiganon, 2009).
Because no widely accepted guidelines exist for neuroprotective MgSo4 therapy at this point, it
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may be advisable to follow guidelines used in successful clinical trials. Also, because both risk
of CP and efficacy of treatment are diminished in infants greater than 32 weeks gestation,
MgSo4 neuroprophylaxis should only be attempted with infants less than 32 weeks.
As outlined in the BEAM trial (Rouse, et al., 2008), and PreMag (Crowther et al., 2003)
a loading dose of 4 gm should be administered followed by a 1 mg/hour infusion up to 24
hours. If labor ceases, the therapy should be stopped but may be re-started if labor resumes
before the patient reaches 32 weeks gestation (Rouse et al., 2008). More data is needed to
determine risks and efficacy of treatment in cases of high risk maternal conditions such as preeclampsia, abruption, and others. Use of prophylactic MgSo4 in these patients should be
avoided until further data is collected.
Parent Education
Because MgSo4 is relatively new and it's physiologic mechanisms poorly understood,
involving parents in the decision to use prophylaxis is essential. This can be complicated as
there are few resources available to parents regarding MgSo4 neuroprophylaxis. This makes a
private and detailed provider consult invaluable. The consult should be performed by a
physician familiar with current literature regarding MgSo4 neuroprophylaxis, and should be
presented in relation to the family's specific risk factors, such as the infant's gestation and
corresponding risk of CP. This should be a realistic discussion of the potential benefits and
side-effects of MgSo4 administration. Parents should be encouraged to ask questions and
repeat back what they understand the risks and potential benefits to be. Once the initial consult
is completed, the parents can be referred to websites such as the March of Dimes
http://www.marchofdimes.com/birthdefects_cerebralpalsy.html and "4 My Child"
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http://www.cerebralpalsy.org/cerebral-palsy-causes/premature-birth/ to assist parents in
understanding the various risk factors associated with pre-term birth, the range of disabilities
associated with CP, as well as finding reassurances they (the parents) did not do anything to
"cause" their child to have CP. This is a difficult position for providers as it is important for
parents to understand the risks to their baby, but the information needs to be provided in a way
that does not induce panic in the parents.
Conclusion
Premature birth is becoming more common with infants surviving birth at extremely
young ages (Crowther, 2010). Many of these extremely premature infants' baseline risk of CP is
nearly 20% with no prophylactic treatments available. Decades of MgSo4 use in obstetric care,
as well as a preponderance of evidence gathered in the trials discussed above, have
demonstrated the risk of MgSo4 therapy to be minimal, and side-effects reversible. This must
be weighed against the risk for CP which can be substantial and the associated handicaps
irreversible. Available evidence suggests neuroprophylactic MgSo4 provides a reasonable
chance to prevent one of the most common and debilitating conditions associated with
prematurity and should be offered to parents who face imminent delivery of an extremely
premature infant.

15

Running head Running Head: NEUROPROTECTIVE EFFECTS

References
Altman, Carroli, Duley, Farrell, Moodley, Neilson, and Smith (2002). Do women with preeclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a
randomised placebo-controlled trial. Lancet, 359(9321):1877-90.
Cahill, Stout, Caughey (2010). Intrapartum magnesium for prevention of cerebral palsy:
continuing controversy? Current Opinion in Obstetrics and Gynecology, 122-127
Constantine and Weiner (2009). Effects of antenatal exposure to magnesium sulfate on
neuroprotecion and mortality in preterm infants: a meta-analysis. American College of
Obstetricians and gynecologists, 2 (114); 354-64
Crowther, Hiller, Doyle, and Haslam (2003). Effect of magnesuim sulfate given for
neuroprotection before preterm birth: a randomized controlled trial. Journal of the
American Medical Association, 290 (20), 2669-2676.
Crowther, Middleton, Marret, and Rouse (2010). Magnesium sulphate for women at risk of
preterm birth for neuroprotection of the fetus. The Cochrane Database of Systematic
Reviews 2009, Issue 1. Art. No.: CD004661. Doi:10.1002/14651858.cd004661.pub3
Doyle, Crowther, Middleton, Marret, & Rouse (2009). Magnesium sulphate for
women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of
Systematic Reviews, (1)
Hayes, C. (2010). Cerebral palsy: classification, diagnosis and challenges of care. British Journal
of Nursing (BJN), 19(6), 368-373.
Hankins, G., and Speer, M. (2003) Defining the pathogenesis and pathophysiology of neonatal
encephalopathy and cerebral palsy. The American College of Obstetricians and
Gynecologists, 102(3), 628-636. doi:10.1016/S0029-7844(03)00574-X
Honeycut A., Dunlap, L., Chen, H., al Homsi, G., Grosse S., Schendel, D., (2003). Economic

16

Running head Running Head: NEUROPROTECTIVE EFFECTS

costs associated with mental retardation, cerebral palsy, hearing loss, and vision
impariment. MMWR 53: 57-9.
Lawson, R., Badawi, N. (2003) Etiology of cerebral palsy. Hand Clinic, 19(4):547-56.
Lumbiganon (2009). Magnesium sulfate for women at risk of preterm birth for neuroprotection
of the fetus: RHL commentary. The WHO Reproductive Health Library; Geneva: World
Health Organization.
http://apps.who.int/rhl/pregnancy_childbirth/complications/preterm_birth/cd004661_lum
biganonp_com/en/index.html
MacDonald, M., Mullett, M., Seshia, M., (Ed) (2005). Avery's neonatology, pathophysiology,
and management of the newborn. 6th ed. Philadelphia, PA: Lippincott, Williams, &
Wilkins.
Marret, Doyle, Crowther, and Middleton (2007). Antenatal magnesium sulphate neuroprotection
in the preterm infant. Seminars in Fetal & Maternal Medicine, 12, 311-317
Marret, Marpeau, and Benichou (2008). Benefit of magnesium sulfate given before very preterm
birth to protect infant brain. Pediatrics, 121 (1) 225-226 (doi:10.1542/peds.2007-2971)
Mittendorf, Dambrosia, Pryde, Lee, Gianopoulos, Besinger, and Tomich (2002). Association
between the use of antenatal magnesium sulfate in preterm labor and adverse health
outcomes in infants. American Journal of Obstetrics and Gynecology, 186(6):1111-8
Nelson and Grether (1995). Can magnesium sulfate reduce the risk of cerebral palsy in very low
birthweight infants? Pediatrics, 95, 263-269.
Odding, Roebroeck, and Stam (2006). The epidemiology of cerebral palsy: incidence,
impairments and risk factors. Disability and Rehabilitation, 28(4):183-91
O'Shea (2008). Cerebral Palsy. Seminars in Perinatology, 35-41;
doi 10.1053/j.semperi.2007.12.008

17

Running head Running Head: NEUROPROTECTIVE EFFECTS

Perlman, J. (2006). Intervention strategies for neonatal hypoxic-ischemic cerebral injury.
NICHD/FDA Newborn Drug Development Initiative workshop, March 29-30, 2004.
Baltimore, MD. Clinical Terapeutics, 28(9), 1353-1365.
Reddihough and Collins (2003). The epidemiology and causes of cerebral palsy. Australian
Journal of Physiotherapy. 49, 7-12
Rouse, Hirtz, Thom, Varner, Spong, Mercer, Iams, Wapner, Sorokin, Alexander, Harper, Thorp,
Ramin, Malone, Carpenter, Miodovnik, Moawad, O'Sullivan, Peaceman, Hankins,
Langer, Caritis, Roberts (2008). A randomized, controlled trial of magnesium sulfate for
the prevention of cerebral palsy. New England Journal of Medicine, 359:895-905.
Simhan and Himes (2010). Neuroprotective effects of in utero exposure to magnesium sulfate.
http://www.uptodate.com/contents/neuroprotective-effects-of-in-utero-exposure-tomagnesium-sulfate
Stanley and Crowther 92008). Antnaal magnesium sulfate for neuroprotection before preterm
birth. New England Journal of Medicine, 359 (9), 962-964
U.S. National Institutes of Health (2010). Beneficial effects of antenatal magnesium sulfate
(BEAM Trial). http://clinicaltrials.gov/ct2/show/NCT00014989
Yeargin-Allsopp, M., K, Doernberg, N., Benedict, R., Kirby, R., & Durkin, M. (2008).
Prevalence of cerebral palsy in 8-year-old children in three areas of the United States in
2002: a multisite collaboration. Pediatrics, 121(3), 547-554.

